We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
GenMark Diagnostics Inc | NASDAQ:GNMK | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 24.05 | 23.92 | 24.39 | 0 | 01:00:00 |
Date of Report (Date of earliest event reported): August 4, 2020
|
||
GENMARK DIAGNOSTICS, INC.
|
||
(Exact name of registrant as specified in its charter)
Commission File Number: 001-34753
|
Delaware | 27-2053069 | |||||||
(State or other jurisdiction
of incorporation) |
(I.R.S. Employer
Identification No.) |
5964 La Place Court
Carlsbad, California 92008
|
||
(Address of principal executive offices, including zip code) |
760-448-4300
|
||
(Registrant’s telephone number, including area code) | ||
(Former Name or Former Address, if Changed Since Last Report) |
Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||||||||||||||
Title of each class |
Trading
Symbol(s) |
Name of each exchange on which registered | ||||||||||||||||||||||||
Common Stock, par value $0.0001 per share | GNMK | The Nasdaq Global Market |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | ||
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
||
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
||
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
||
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). | ||
Emerging Growth Company o
|
||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Selection 13(a) of the Exchange Act. o
|
(d) | The following exhibit is furnished with this Current Report: | ||||
99.1 |
Press release dated August 4, 2020
|
GENMARK DIAGNOSTICS, INC. | ||||||||
Date: |
August 4, 2020
|
/s/ Johnny Ek | ||||||
Johnny Ek | ||||||||
Chief Financial Officer | ||||||||
Exhibit
Number |
Description
|
|||||||
1 Year GenMark Diagnostics Chart |
1 Month GenMark Diagnostics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions